[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. López-Quero MC, Casas-Fernández A, Lucas-Elío G, Rodríguez-González-Herrero ME, Marín-Sánchez JM: [Circumscribed choroidal hemangioma treated with photodynamic therapy]. Arch Soc Esp Oftalmol; 2008 Sep;83(9):553-7
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Circumscribed choroidal hemangioma treated with photodynamic therapy].
  • [Transliterated title] Hemangioma circunscrito de coroides tratado con terapia fotodinámica.
  • It was diagnosed as a circumscribed choroidal hemangioma.
  • It was decided to treat the patient using photodynamic therapy.
  • DISCUSSION: Photodynamic therapy is a good option for the treatment of circumscribed choroidal hemangioma given the minimal damage is causes to the adjacent retina.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803129.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Suh SC, Jin SY, Bae SH, Kim CG, Kim JW: Retinal capillary hemangioma treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide. Korean J Ophthalmol; 2007 Sep;21(3):178-84
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide.
  • PURPOSE: To report a case of retinal capillary hemangioma treated with verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide.
  • Examination showed peripheral endophytic retinal capillary hemangioma, macular edema, and a best-corrected visual acuity of 20/50.
  • The hemangioma and macular edema were treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide.
  • RESULTS: After 5 months of follow-up, involution of the hemangioma, reduction of macular edema, decrease of the feeder and draining vessel diameter, and improvement of best-corrected visual acuity to 20/25 was seen.
  • CONCLUSIONS: This verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide appeared to cause involution of the hemangioma with reduction in macular edema and improvement in visual acuity.
  • [MeSH-major] Glucocorticoids / administration & dosage. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy. Triamcinolone Acetonide / administration & dosage
  • [MeSH-minor] Adolescent. Female. Fundus Oculi. Humans. Injections. Tomography, Optical Coherence. Ultrasonography. Vitreous Body

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1999 Oct;117(10):1329-45 [10532441.001]
  • [Cites] Can J Ophthalmol. 2005 Apr;40(2):192-4 [16049535.001]
  • [Cites] Arch Ophthalmol. 2001 Feb;119(2):232-4 [11176984.001]
  • [Cites] Arch Ophthalmol. 2001 Mar;119(3):399-404 [11231773.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):541-60 [11336929.001]
  • [Cites] Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42 [11578646.001]
  • [Cites] Ophthalmology. 2001 Oct;108(10):1907-11 [11581072.001]
  • [Cites] Retina. 2002 Apr;22(2):228-32 [11927862.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2002 Jan;240(1):42-8 [11954780.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3125-30 [12202538.001]
  • [Cites] Am J Ophthalmol. 2002 Nov;134(5):788-90 [12429270.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1517-25 [12917166.001]
  • [Cites] Trans Am Ophthalmol Soc. 1970;68:367-424 [5535648.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 May-Jun;83(3 Pt 1):OP432-42 [888256.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 May-Jun;83(3 Pt 1):OP446-53 [888257.001]
  • [Cites] Can J Ophthalmol. 1986 Dec;21(7):276-83 [3801976.001]
  • [Cites] Ophthalmology. 1996 Feb;103(2):329-35 ; discussion 334-5 [8594522.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):62-3 [10691410.001]
  • (PMID = 17804927.001).
  • [ISSN] 1011-8942
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Photosensitizing Agents; 0 / Porphyrins; 0X9PA28K43 / verteporfin; F446C597KA / Triamcinolone Acetonide
  • [Other-IDs] NLM/ PMC2629681
  •  go-up   go-down


3. Sagong M, Lee J, Chang W: Application of intravitreal bevacizumab for circumscribed choroidal hemangioma. Korean J Ophthalmol; 2009 Jun;23(2):127-31
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of intravitreal bevacizumab for circumscribed choroidal hemangioma.
  • We report 3 cases of circumscribed choroidal hemangioma (CCH) effectively managed with intravitreal bevacizumab.
  • Two patients (case 2 and 3) who had CCH (2.4 mm and 2.2 mm in thickness, respectively) with recent visual impairment were treated with bevacizumab followed by photodynamic therapy (PDT).
  • Ophthalmic evaluations included visual acuity, ophthalmoscopic examination, fluorescein angiography, ultrasonography, and optical coherence tomography.
  • After therapy, all patients showed improved visual acuity due to complete resorption of subretinal fluid and macular edema.
  • Intravitreal bevacizumab, alone or in combination therapy with PDT, may be a useful alternative for the treatment of symptomatic CCH with subretinal fluid.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Choroid Neoplasms / drug therapy. Hemangioma / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Injections. Male. Middle Aged. Ophthalmoscopy. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A. Vitreous Body

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2000 Feb;107(2):351-6; discussion 357 [10690838.001]
  • [Cites] Eye (Lond). 2007 Aug;21(8):1125-6 [17545966.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H434-40 [11123261.001]
  • [Cites] Acta Ophthalmol Scand. 2001 Apr;79(2):184-6 [11284760.001]
  • [Cites] Ophthalmology. 2001 Dec;108(12):2237-48 [11733265.001]
  • [Cites] Retina. 2001;21(6):682-4 [11756902.001]
  • [Cites] Ophthalmology. 2002 Dec;109(12):2284-94 [12466172.001]
  • [Cites] Ophthalmology. 2003 Apr;110(4):674-80 [12689885.001]
  • [Cites] Curr Opin Ophthalmol. 2003 Jun;14(3):142-9 [12777933.001]
  • [Cites] Surv Ophthalmol. 1976 May-Jun;20(6):415-31 [820013.001]
  • [Cites] Ann Ophthalmol. 1979 Jan;11(1):100-4 [420470.001]
  • [Cites] Ophthalmology. 1982 Dec;89(12):1374-80 [6891765.001]
  • [Cites] J Natl Cancer Inst. 1988 Nov 2;80(17):1387-92 [3172265.001]
  • [Cites] Arch Ophthalmol. 1989 Sep;107(9):1338-42 [2783066.001]
  • [Cites] Ophthalmology. 1992 Aug;99(8):1278-85 [1325044.001]
  • [Cites] Ophthalmology. 1994 Jan;101(1):89-99 [8302569.001]
  • [Cites] Retina. 1981;1(1):56-61 [15633407.001]
  • [Cites] Ophthalmology. 2005 Jun;112(6):1048-53 [15885778.001]
  • [Cites] Retina. 2005 Sep;25(6):697-703 [16141856.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5 [16156152.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9 [16156153.001]
  • [Cites] Retina. 2006 Mar;26(3):356-7 [16508440.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):148-50 [16583638.001]
  • [Cites] Am J Ophthalmol. 2006 Oct;142(4):685-8 [17011869.001]
  • [Cites] Retina. 2006 Nov-Dec;26(9):999-1005 [17151486.001]
  • [Cites] Eye (Lond). 2007 Jun;21(6):893-4 [17347676.001]
  • [Cites] Arch Ophthalmol. 2007 Jun;125(6):751-6 [17562985.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2000 Mar;238(3):214-21 [10796035.001]
  • (PMID = 19568366.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2694292
  • [Keywords] NOTNLM ; Bevacizumab / Choroidal hemangioma / Photodynamic therapy
  •  go-up   go-down


Advertisement
4. Costa RA, Meirelles RL, Cardillo JA, Abrantes ML, Farah ME: Retinal capillary hemangioma treatment by indocyanine green-mediated photothrombosis. Am J Ophthalmol; 2003 Mar;135(3):395-8
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treatment by indocyanine green-mediated photothrombosis.
  • PURPOSE: To describe the clinical, angiographic and optical coherence tomography (OCT) findings of a patient with a large retinal capillary hemangioma who was treated by indocyanine green-mediated photothrombosis.
  • METHODS: An 18-year-old male patient was treated at a tertiary referral center with a novel laser-dye procedure that uses low-irradiance 810-nm laser and intravenous indocyanine green injection and was prospectively evaluated with fluorescein and indocyanine green angiography, as well as OCT.
  • Fundus photography showed marked reduction of a 3 disk diameters retinal capillary hemangioma.
  • Both fluorescein and indocyanine green angiography demonstrated reduced tumor perfusion and narrowing of the lesion feeder and draining vessels as early as 5 days after indocyanine green-mediated photothrombosis; OCT showed immediate decrease in retinal elevation and complete resolution of subretinal fluid within 2 months of treatment.
  • CONCLUSIONS: Photothrombosis using low-intensity, 810-nm light to direct laser energy continuously at the tumor after intravenous indocyanine green infusion was effective in restoring macular architecture and improving vision in a patient with a large peripheral retinal capillary hemangioma by means of substantial occlusion of the tumor vasculature and resolution of subretinal fluid.
  • [MeSH-major] Coloring Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Indocyanine Green / therapeutic use. Photochemotherapy. Retinal Neoplasms / drug therapy. Retinal Vessels / drug effects
  • [MeSH-minor] Adolescent. Fluorescein Angiography. Humans. Interferometry. Light. Male. Prospective Studies. Thrombosis / etiology. Tomography. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 by Elsevier Science Inc.
  • (PMID = 12614766.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


5. Zhang Y, Liu W, Fang Y, Qian J, Xu G, Wang W, Li L, Shen Y, Gao Q: Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients. Am J Ophthalmol; 2010 Nov;150(5):710-715.e1
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients.
  • PURPOSE: To evaluate the efficacy and safety of photodynamic therapy (PDT) for macular circumscribed choroidal hemangioma in Chinese patients.
  • METHODS: Twenty-five eyes (25 patients) with macular circumscribed choroidal hemangioma, 18 subfoveal and 7 perifoveal, with vision impairment attributable to subfoveal fluid and retinal detachment underwent visual acuity testing, fundus fluorescein angiography, ultrasonography, and optical coherence tomography (OCT) examinations to evaluate the efficacy and safety of PDT treatment.
  • PDT was performed with a standard concentration of verteporfin and intravenous injection time.
  • RESULTS: The mean follow-up time was 35.5 ± 15 months.
  • The remaining 14 patients (56%) had stabilized vision with the retina reattached.
  • The mean thickness of the hemangioma before the treatment was 3.2 ± 0.9 mm and decreased to 1.3 ± 1.0 mm post treatment (P < .01), with complete regression of tumor in 7 cases (28%).
  • CONCLUSIONS: PDT with individualized laser parameters for macular circumscribed choroidal hemangioma is effective and safe, leading to improved or stabilized BCVA as a result of tumor shrinkage and the resolution of the subretinal fluid.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Asian Continental Ancestry Group / ethnology. China / epidemiology. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Macula Lutea. Male. Middle Aged. Retrospective Studies. Tomography, Optical Coherence. Visual Acuity / physiology

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20709311.001).
  • [ISSN] 1879-1891
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


6. Anand R: Photodynamic therapy for diffuse choroidal hemangioma associated with Sturge Weber syndrome. Am J Ophthalmol; 2003 Oct;136(4):758-60
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for diffuse choroidal hemangioma associated with Sturge Weber syndrome.
  • PURPOSE: To report successful treatment of a diffuse choroidal hemangioma associated with chronic retinal detachment.
  • METHODS: A patient with bilateral Sturge Weber syndrome and associated retinal detachments failed external beam radiation.
  • He was then treated with single session, multispot photodynamic therapy with verteporfin.
  • There was prompt resolution of the retinal detachment and significant reduction in thickness of the choroidal hemangioma.
  • CONCLUSION: Verteporfin therapy may be useful in diffuse choroidal hemangiomas.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Sturge-Weber Syndrome / complications
  • [MeSH-minor] Adolescent. Humans. Male. Retinal Detachment / drug therapy. Retinal Detachment / etiology. Retinal Detachment / ultrasonography

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Sturge-Weber syndrome.
  • Genetic Alliance. consumer health - Weber syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516829.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


7. von Buelow M, Pape S, Hoerauf H: Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand; 2007 Feb;85(1):114-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244223.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


8. Boixadera A, García-Arumí J, Martínez-Castillo V, Encinas JL, Elizalde J, Blanco-Mateos G, Caminal J, Capeans C, Armada F, Navea A, Olea JL: Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology; 2009 Jan;116(1):100-105.e1
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma.
  • PURPOSE: To evaluate photodynamic therapy (PDT) for symptomatic circumscribed choroidal hemangioma (CCH).
  • INTERVENTION: Photodynamic therapy was applied by Zeiss laser.
  • Intravenous verteporfin at 6 mg/m(2) body surface was administered before treatment, and light emitted at 689 nm for photosensitization.
  • The treatment spot diameter was calculated on early-phase frames of pretreatment indocyanine green angiography.
  • Fifteen minutes after starting the verteporfin infusion, the laser beam was applied to the retina at radiant exposure 50 J/cm(2) and exposure time 83 seconds.
  • One to 4 treatments were applied at 12-week intervals over 1 year.
  • Standardized evaluation was performed before and at 4-week intervals after each treatment, and at 3, 6, 9, and 12 months.
  • MAIN OUTCOME MEASURES: The primary outcome measure was the absence of exudative retinal detachment at the 12-month follow-up visit on ophthalmoscopy, fluorescein angiography, and optical coherence tomography.
  • Secondary measures were the visual acuity outcome, with best-corrected visual acuity determined by the Early Treatment for Diabetic Retinopathy Study chart, tumor thickness decrease on B-scan ultrasonography, and adverse events.
  • RESULTS: Among the total, 82.8% of patients required 1, 13.8% 2, and 3.4% 3 PDTs to eliminate exudative retinal detachment.
  • The CCH thickness decreased in all cases from a mean of 3.0 to 1.7 mm, with the most intense effect seen after 4 weeks of treatment (P<0.001).
  • CONCLUSIONS: Combining PDT with the standard age-related macular degeneration protocol is an effective treatment for CCH in terms of resolution of exudative subretinal fluid and recovery of VA.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ophthalmology. 2009 May;116(5):822. Arumí, José García [corrected to García-Arumí, José]
  • (PMID = 18973950.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


9. Mennel S, Barbazetto I, Meyer CH, Peter S, Stur M: Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience. Ophthalmologica; 2007;221(4):216-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience.
  • Ocular photodynamic therapy (PDT) was introduced as a novel treatment for neovascular forms of age-related macular degeneration and choroidal neovascularization (CNV) secondary to pathologic myopia in the mid/end 1990s.
  • The current treatment recommendations are based on the results of two large, prospective, multicenter, randomized clinical trials (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Studies) and thousands of patients have been treated worldwide over the last years.
  • These extended applications include CNV secondary to choroiditis and retinochoroiditis, angioid streaks, central serous chorioretinopathy, retinal angiomatous proliferation, parafoveal telangiectasia or CNV associated with macular dystrophy and idiopathic CNV, as well as diseases without CNV, such as choroidal hemangioma, retinal hamartoma, choroidal melanoma, chronic central serous chorioretinopathy, angiomatous lesions secondary to systemic diseases, rubeosis iridis or neovascular glaucoma.
  • To date, with the introduction of anti-VEGF therapy, the role of PDT will certainly change.
  • However, it is reasonable to believe that it will maintain an important role in combination therapy due to its unique properties of selective vascular targeting.
  • Therefore, it is essential for the ophthalmologist to be familiar with the extended applications and their modifications of treatment parameters.
  • [MeSH-major] Choroidal Neovascularization / drug therapy. Glaucoma, Neovascular / drug therapy. Iris / blood supply. Neovascularization, Pathologic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Humans. Retinal Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17579286.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  • [Number-of-references] 89
  •  go-up   go-down


10. Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL 3rd, Chew EY: Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina; 2007 Feb;27(2):150-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
  • OBJECTIVE: This pilot study was designed to provide preliminary data concerning the safety and efficacy of pegylated anti-vascular endothelial growth factor (VEGF) therapy, pegaptanib, for patients with juxtapapillary or large peripheral angiomas secondary to von Hippel-Lindau (VHL) disease.
  • Secondary outcomes included changes in macular thickness, as determined by optical coherence tomography, and changes in fluorescein leakage.
  • RESULTS: Two of five patients completed the course of treatment and 1 year of follow-up.
  • These two patients had progressive decrease in retinal hard exudate and reduction in central retinal thickness measured by optical coherence tomography.
  • Lesions in the other three patients continued to progress despite treatment, and these patients did not complete the entire treatment course.
  • One patient developed a tractional retinal detachment.
  • CONCLUSIONS: Intravitreal injections of anti-VEGF therapy (pegaptanib) may decrease retinal thickening minimally and reduce retinal hard exudates in some patients with advanced VHL angiomas.
  • This finding may be related to a reduction in vasopermeability, because there was no apparent effect of treatment on the size of the primary retinal angiomas in this small pilot study.
  • [MeSH-major] Aptamers, Nucleotide / therapeutic use. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. von Hippel-Lindau Disease / drug therapy
  • [MeSH-minor] Adult. Female. Fluorescein Angiography. Humans. Injections. Male. Middle Aged. Pilot Projects. Prospective Studies. Tomography, Optical Coherence. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290195.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 EY999999; United States / Intramural NIH HHS / / ZIE EY000487-01
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / pegaptanib
  •  go-up   go-down


11. Hussain N, Das T, Ram LS, Sumasri K: Persistent choroidal thickening despite photodynamic therapy for circumscribed choroidal hemangioma. Ophthalmic Surg Lasers Imaging; 2006 Jan-Feb;37(1):76-8
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent choroidal thickening despite photodynamic therapy for circumscribed choroidal hemangioma.
  • A 19-year-old man presented with blurred vision in the right eye, which was diagnosed as a circumscribed choroidal hemangioma.
  • The choroidal thickening on B-scan ultrasonography persisted after receiving repeat photodynamic therapy with verteporfin, although there was regression of the tumor.
  • [MeSH-major] Choroid. Choroid Neoplasms / surgery. Hemangioma / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468558.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


12. Javellana JA, Drouilhet JH, Kokame GT, Chee PH, Wong BM: Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy. Am J Ophthalmol; 2004 Apr;137(4):780-2
Genetic Alliance. consumer health - Familial exudative vitreoretinopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy.
  • PURPOSE: To report a case of familial exudative vitreoretinopathy with a retinal capillary angioma and persistent macular exudation treated with photodynamic therapy.
  • METHODS: A 39-year-old woman with familial exudative vitreoretinopathy presented with an intraretinal capillary angioma temporally with persistent macular exudation despite previous vitrectomy and thermal laser.
  • Photodynamic therapy to the retinal angioma was performed.
  • RESULTS: Three months after photodynamic therapy, vision was stable at 20/200 with a reduction in lesion size on B-scan ultrasonography and no leakage on fluorescein angiography.
  • CONCLUSION: Retinal capillary angioma may be present in association with familial exudative vitreoretinopathy, and photodynamic therapy may provide a good alternative treatment to decrease exudation.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy. Vitreoretinopathy, Proliferative / genetics
  • [MeSH-minor] Adult. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Laser Coagulation. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Visual Acuity. Vitrectomy

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15059735.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


13. Bosch MM, Helbig H: Blackening of a choroidal hemangioma after photodynamic therapy. Klin Monbl Augenheilkd; 2005 Mar;222(3):258-60
MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blackening of a choroidal hemangioma after photodynamic therapy.
  • BACKGROUND: Photodynamic therapy has recently advanced to a first line treatment of symptomatic circumscribed choroidal hemangiomas.
  • Thickening of the central retina was seen on OCT imaging.
  • THERAPY AND OUTCOME: The hemangioma was treated with verteporphin photodynamic therapy.
  • Two days after treatment, with vision unchanged, fundus examination revealed blackening of the tumor.
  • Angiography revealed the disappearance of tumor vessels and choroidal hypoperfusion in the area of treatment.
  • CONCLUSIONS: Choroidal hemangiomas may darken initially after photodynamic therapy.
  • This is most probably caused by large coaguli within the voluminous lacuna-like blood-filled vessel system of the hemangioma that are induced by photothrombosis.
  • [MeSH-major] Choroid / pathology. Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Hematoporphyrin Photoradiation. Pigmentation Disorders / etiology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785995.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Soucek P, Cihelková I: Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with Verteporfin. Neuro Endocrinol Lett; 2004 Feb-Apr;25(1-2):109-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with Verteporfin.
  • PURPOSE: To determine if optical coherence tomography (OCT) measurements of retinal thickness at the fixation point (RTFP) can be used to confirm the effectiveness of photodynamic therapy (PDT) with verteporfin in the treatment of symptomatic circumscribed choroidal hemangioma (CCH).
  • Maximal decrease of RTFP was seen within first month after treatment.
  • An improvement in BCVA was observed in all cases (100%, one to seven lines on Early Treatment Diabetic Retinopathy Study charts).
  • CONCLUSIONS: OCT appears to be useful method for evaluation of subretinal fluid absorption after the treatment of CCH by PDT with verteporfin.
  • Functional results of PDT with verteporfin in CCH are limited in pre-existing retinal alterations.
  • [MeSH-major] Body Fluids / metabolism. Choroid Neoplasms / drug therapy. Fovea Centralis / pathology. Hemangioma / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Tomography, Optical Coherence / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retina / drug effects. Retina / metabolism. Retina / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15159693.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


15. Robertson DM: Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment. Arch Ophthalmol; 2002 Sep;120(9):1155-61
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment.
  • OBJECTIVE: To describe the clinical findings in 3 eyes with circumscribed choroidal hemangioma before and after treatment with photodynamic therapy.
  • PATIENTS AND METHODS: In the setting of a tertiary referral center, 2 patients with circumscribed, posteriorly located, choroidal hemangiomas (thicknesses 2.4 and 2.9 mm) contiguous with the superior boundary of the optic nerve and accompanied by serous detachments of the sensory retina extending into the macula were treated with photodynamic therapy using a Zeiss diode laser (692 nm) and a sensitizing dye, verteporfin.
  • A third patient with a circumscribed subfoveal hemangioma (3.9 mm in thickness) and a prominent serous retinal detachment was similarly treated.
  • RESULTS: Following photodynamic therapy, the serous retinal detachments resolved, and the choroidal hemangioma in each of the 3 eyes regressed to a nonmeasurable thickness within 2 to 5 months.
  • CONCLUSIONS: Photodynamic therapy seems to be effective in the management of circumscribed choroidal hemangioma.
  • Following photodynamic therapy, the choroidal hemangiomas in 3 eyes were no longer measurable by ultrasonography, and the accompanying serous detachments resolved with improvement in the central visual acuities.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Detachment / drug therapy
  • [MeSH-minor] Aged. Fluorescein Angiography. Humans. Male. Middle Aged. Treatment Outcome. Visual Acuity. Visual Field Tests. Visual Fields

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215088.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


16. Michels S, Michels R, Simader C, Schmidt-Erfurth U: Verteporfin therapy for choroidal hemangioma: a long-term follow-up. Retina; 2005 Sep;25(6):697-703
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verteporfin therapy for choroidal hemangioma: a long-term follow-up.
  • BACKGROUND: To document the long-term follow-up of patients with circumscribed choroidal hemangioma who were treated with verteporfin photodynamic therapy (PDT).
  • Chorioretinal atrophy at the previous tumor site did not enlarge over time.
  • Retreatments after completion of the primary treatment were not necessary.
  • CONCLUSION: Persistent and complete absence of choroidal hemangioma associated with persistent improvement in visual acuity and central visual fields can be obtained with verteporfin PDT.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Fluorescein Angiography. Follow-Up Studies. Humans. Indocyanine Green. Prospective Studies. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16141856.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


17. Shields CL, Materin MA, Marr BP, Mashayekhi A, Shields JA: Resolution of advanced cystoid macular edema following photodynamic therapy for choroidal hemangioma. Ophthalmic Surg Lasers Imaging; 2005 May-Jun;36(3):237-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of advanced cystoid macular edema following photodynamic therapy for choroidal hemangioma.
  • His visual acuity was 20/200 secondary to a subtle juxtapapillary choroidal hemangioma producing profound cystoid macular edema, with the affected retina measuring 330 microns thick by optical coherence tomography.
  • One month following photodynamic therapy to the tumor using verteporfin, the cystoid macular edema completely resolved, foveal anatomy returned to normal, optical coherence tomography thickness was 179 microns, and visual acuity recovered to 20/25.
  • Photodynamic therapy of choroidal hemangioma may be effective in resolving associated cystoid macular edema and improving visual acuity.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Macular Edema / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Fluorescein Angiography. Humans. Male. Middle Aged. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957481.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


18. Atebara NH: Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol; 2002 Nov;134(5):788-90
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treated with verteporfin photodynamic therapy.
  • PURPOSE: To describe a case of exudative retinal capillary hemangioma treated with photodynamic therapy that resulted in an improvement in clinical appearance and visual acuity.
  • METHODS: A 55-year-old Asian man presented with a large exudative peripheral retinal capillary hemangioma of the left eye causing serous retinal detachment, cystoid macular edema, and a best-corrected visual acuity of 20/200.
  • The hemangioma was treated with three successive sessions of verteporfin photodynamic therapy (PDT).
  • RESULTS: With 10 months of follow-up after the initial treatment, involution of the hemangioma, reduction of subretinal fluid, and improvement of best-corrected visual acuity to 20/80 was seen.
  • CONCLUSION: Photodynamic therapy may be an effective treatment option in select cases of exudative retinal capillary hemangioma.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Exudates and Transudates. Humans. Male. Middle Aged. Retinal Detachment / etiology. Retinal Vessels / pathology. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429270.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


19. Su ZA, Shen J, Yao K, Zhang LX, Teng Y: [Combination facula photodynamic therapy for circumscribed choroidal hemangioma]. Zhonghua Yan Ke Za Zhi; 2008 Sep;44(9):790-3
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination facula photodynamic therapy for circumscribed choroidal hemangioma].
  • OBJECTIVE: To assess the clinical effect of combination facula photodynamic therapy (PDT) on patients with circumscribed choroidal hemangioma.
  • Ten cases of circumscribed choroidal hemangioma were diagnosed by ophthalmoscopy, fundus fluorescein angiography and B-scanning ultrasound examination.
  • Four patients suffered from retinal detachment The intravenous injection of visudyne (6 mg/m2) was performed in 10 minutes.
  • RESULTS: The visual acuity in the last examination after treatment was FC-1.0, which was 2-line increased in 7 patients and was steady in 3 patients.
  • B-scanning ultrasound examination showed that the hemangioma was undetectable in 2 patients, and in the other 8 patients,the hemangioma had the diameter of 4.2 to 8.3 mm (average 6.4 mm) and the thickness was 0.5 to 2.7 mm (average 1.9 mm).
  • Retina detachment disappeared in 2 patients CONCLUSIONS: Combination facula PDT may lead to the shrinking of choroidal hemangioma, disappearance of subretinal fluid, reattachment of retina and the increase or saving of the visual acuity.
  • It is a effective and safe treatment for the macular circumscribed choroidal hemangioma.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175157.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Porrini G, Giovannini A, Amato G, Ioni A, Pantanetti M: Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology; 2003 Apr;110(4):674-80
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of circumscribed choroidal hemangioma.
  • PURPOSE: To evaluate the safety and effectiveness of photodynamic therapy (PDT) in the treatment of symptomatic circumscribed choroidal hemangiomas (CCH) of the posterior pole.
  • METHODS: Photodynamic therapy was applied by Zeiss laser (Visulas 6905, Carl Zeiss-Meditech AG, Jeud Germany) emitting a light at 689 nm for photosensitization and by using verteporfin (Visudyne; Novartis Ophthalmics AG, Basel, Switzerland) at a dose of 6 mg/m(2) body surface administered intravenously before treatment.
  • The diameter of the treatment spot was calculated on early frames of pretreatment indocyanine green angiography; the maximum treatment spot diameter was 6000 micro m using a Mainster wide-field lens (Ocular Instruments Inc., Bellevue, WA USA).
  • A laser beam was applied to the retina 15 minutes after the start of the infusion.
  • Two different treatment procedures were used according to the height of the lesion.
  • A radiant exposure of 100 J/cm(2) with an exposure time of 186 seconds was applied to lesions larger than 2 mm.
  • For lesions smaller than 2 mm, a radiant exposure of 75 J/cm(2) with an exposure time of 125 seconds was used.
  • No retinal pigment epithelium (RPE) changes were observed in the patients who had undergone two PDT treatments, whereas minimal alterations were detected in two of the four patients who had undergone three treatment sessions.
  • Ultrasound examination found no measurable tumor height in six (60%) cases and a marked reduction in the remaining four cases, even after one treatment (post treatment tumor height range, 0.86-1.82 mm).
  • An improvement in visual acuity (one to six lines on the Early Treatment for Diabetic Retinopathy Study chart) was observed in all the cases.
  • In all cases no damage to retinal vessels was observed.
  • CONCLUSIONS: Photodynamic therapy is a minimally invasive but effective method of treatment for CCH and may be considered as a treatment of choice, especially in patients with foveal location of the tumor.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Safety. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689885.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


21. van Emelen C, Goethals M, Dralands L, Casteels I: Treatment of glaucoma in children with Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus; 2000 Jan-Feb;37(1):29-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of glaucoma in children with Sturge-Weber syndrome.
  • BACKGROUND: Sturge-Weber syndrome is a rare congenital neuro-oculocutaneous disorder.
  • Ocular involvement can include glaucoma and vascular malformations of the conjunctiva, episclera, choroid, and retina.
  • Other ocular manifestations included conjunctival/episcleral hemangioma, choroidal hemangioma, iris heterochromia, retinal detachment, strabismus, and homonymous hemianopia.
  • In 7 of 8 patients with glaucoma, topical pharmacotherapy (beta-blockers and carbonic anhydrase inhibitors) alone failed to normalize intraocular pressures.
  • CONCLUSIONS: Cryocoagulation of the ciliary body combined with topical medication is an effective and safe treatment option in the management of glaucoma in children with Sturge-Weber syndrome.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Carbonic Anhydrase Inhibitors / therapeutic use. Ciliary Body / surgery. Cryosurgery. Glaucoma / surgery. Sturge-Weber Syndrome / complications
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Therapy, Combination. Eye Diseases / etiology. Female. Humans. Infant. Intraocular Pressure. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Glaucoma.
  • Genetic Alliance. consumer health - Sturge-Weber syndrome.
  • Genetic Alliance. consumer health - Weber syndrome.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714693.001).
  • [ISSN] 0191-3913
  • [Journal-full-title] Journal of pediatric ophthalmology and strabismus
  • [ISO-abbreviation] J Pediatr Ophthalmol Strabismus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Carbonic Anhydrase Inhibitors
  •  go-up   go-down


22. Lo Giudice G, Gismondi M, De Belvis V, Cian R, Tavolato M, Galan A: Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation. Retina; 2009 Jul-Aug;29(7):949-55
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation.
  • PURPOSE: To evaluate the efficacy of single-session photodynamic therapy (PDT) combined with intravitreal bevacizumab (IVB) in the treatment of retinal angiomatous proliferation (RAP) in age-related macular degeneration.
  • All patients were naïve to treatment.
  • Best-corrected visual acuity (BCVA), fluorescein angiography, ICGA, and optical coherence tomography (OCT) were performed at baseline and at each follow-up visit.
  • A significant improvement in the mean BCVA was observed at 1 month, 3 months, 6 months, and 9 months after combined treatment (P = 0.004).
  • Mean central macular thickness was significantly reduced in all patients (P < 0.0001) as controlled at 1-month, 3-month, 6-month, and 9-month intervals from initial treatment.
  • No ocular complications or systemic events developed.
  • CONCLUSION: Sequenced combined treatment with single-session PDT and IVB injections may be useful in treating RAP, reducing or eliminating retinal edema, and improving or stabilizing visual acuity.
  • Further investigations are warranted to outline the appropriate treatment paradigm for combination therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Hemangioma / drug therapy. Photochemotherapy / methods. Retinal Diseases / drug therapy. Vitreous Body
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Coloring Agents. Drug Administration Schedule. Drug Therapy, Combination. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Indocyanine Green. Injections. Macular Degeneration / complications. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Pilot Projects. Porphyrins / therapeutic use. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity / drug effects

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584653.001).
  • [ISSN] 1539-2864
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; 2S9ZZM9Q9V / Bevacizumab; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


23. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A, Ladas ID: Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina; 2009 Apr;29(4):536-44
Hazardous Substances Data Bank. TRIAMCINOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study.
  • PURPOSE: To compare 1) intravitreal ranibizumab, 2) intravitreal ranibizumab plus photodynamic therapy (PDT), and 3) intravitreal triamcinolone plus PDT in retinal angiomatous proliferation.
  • METHODS: In this prospective study, 37 eyes of 37 patients with retinal angiomatous proliferation were randomly assigned in 1 of the 3 groups.
  • Retreatment, with the same therapeutic scheme in each group, was considered in case of persistence or recurrence of subretinal fluid or intraretinal fluid.
  • The mean central retinal thickness reduction in Group 1 was 32.23 mum (P = 0.548), in Group 2 20.31 mum (P = 0.042), and in Group 3 73.92 mum (P < 0.0001).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Glucocorticoids / administration & dosage. Hemangioma / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy. Triamcinolone / administration & dosage
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Drug Therapy, Combination. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Injections. Male. Ranibizumab. Retina / drug effects. Retina / pathology. Time Factors. Treatment Outcome. Visual Acuity / drug effects. Vitreous Body

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Retina. 2010 Jun;30(6):981; author reply 981 [20531149.001]
  • (PMID = 19190547.001).
  • [ISSN] 1539-2864
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glucocorticoids; 1ZK20VI6TY / Triamcinolone; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down


24. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology; 2002 Jul;109(7):1256-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefits and complications of photodynamic therapy of papillary capillary hemangiomas.
  • OBJECTIVE: To evaluate the potential benefit and risks of photodynamic therapy (PDT) in the treatment of papillary capillary hemangioma.
  • PARTICIPANTS: Five patients with solitary capillary hemangioma on the temporal portion of the optic nerve presenting with exudative decompensation and decrease in visual acuity (VA).
  • METHODS: All eyes received a standardized PDT treatment with 6 mg/kg body surface area verteporfin and application of 100 J/cm(2) light at 692 nm.
  • A continuous follow-up was provided with documentation 1 week before and at 4 to 6 weeks, 3 months, and 12 months after the last treatment application.
  • MAIN OUTCOME MEASURES: Functional parameters included best-refracted VA (Early Treatment Diabetic Retinopathy Study), and central scanning laser ophthalmoscope (SLO) scotometry and peripheral (automated perimetry) visual fields; anatomic parameters were presence of retinal edema or serous detachment (ophthalmoscopy) and tumor size (ultrasonography).
  • Tumor regression with resolution of macular exudate and serous retinal detachment was obtained in all eyes.
  • Complications included transient decompensation of vascular permeability, occlusion of retinal vessels, and ischemia of the optic nerve.
  • Vaso-occlusive effects at the level of the retina and optic nerve compromise the functional benefit.
  • Parameters proven safe in choroidal neovascularization may be inappropriate in retinal capillary lesions of the optic nerve.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Optic Disk / blood supply. Optic Nerve Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Capillary Permeability / drug effects. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Ophthalmoscopy. Optic Neuropathy, Ischemic / chemically induced. Prospective Studies. Retinal Artery Occlusion / chemically induced. Retinal Vein Occlusion / chemically induced. Visual Acuity. Visual Fields

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12093647.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


25. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E: Photodynamic therapy for vasoproliferative retinal tumors. Retina; 2006 Apr;26(4):404-9
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for vasoproliferative retinal tumors.
  • PURPOSE: To report our experience with photodynamic therapy (PDT) with verteporfin for patients with vasoproliferative retinal tumors (VPRTs).
  • Biomicroscopy, fluorescein angiography, indocyanine green angiography, optical coherence tomography, and ultrasonography were performed before treatment and 1 month, 3 months, 6 months, and 1 year after treatment; visual acuity was measured using Early Treatment Diabetic Retinopathy Study criteria.
  • RESULTS: At the 1-year follow-up, all tumors responded with a reduction in size (mean height: pretreatment, 2.96 mm; posttreatment, 1.32 mm), and optical coherence tomography showed complete resolution of macular exudates.
  • An improvement in visual acuity (average, 4.7 Early Treatment Diabetic Retinopathy Study letters) was observed.
  • CONCLUSION: PDT may represent an effective and safe modality of treatment for VPRTs because of its selectivity.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Coloring Agents. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Retinal Hemorrhage / diagnosis. Retinal Hemorrhage / drug therapy. Retinal Vessels / drug effects. Tomography, Optical Coherence. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603958.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


26. Barbezetto IA, Smith RT: Vasoproliferative tumor of the retima treated with PDT. Retina; 2003 Aug;23(4):565-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Photochemotherapy. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fluorescein Angiography. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972778.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


27. Sahu AK, Narayanan R: Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation. Retina; 2010 Jun;30(6):981; author reply 981
Hazardous Substances Data Bank. TRIAMCINOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Glucocorticoids / administration & dosage. Hemangioma / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy. Triamcinolone / administration & dosage
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Drug Therapy, Combination. Fluorescein Angiography. Humans. Injections. Ranibizumab. Retina / drug effects. Retina / pathology. Time Factors. Treatment Outcome. Visual Acuity / drug effects. Vitreous Body

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Retina. 2009 Apr;29(4):536-44 [19190547.001]
  • (PMID = 20531149.001).
  • [ISSN] 1539-2864
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glucocorticoids; 1ZK20VI6TY / Triamcinolone; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down






Advertisement